Castration-Resistant Prostate Cancer: Progress and Promise
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".
Deadline for manuscript submissions: closed (31 March 2024) | Viewed by 396
Special Issue Editors
Interests: translational research; castrate-resistant prostate cancer; stem cell and CRPC; cancer cell metabolism; data science; cell signaling; immunotherapy
Interests: proteomics; translational research; antibody and therapeutic; brain research; neurodegenerative disease; cell signaling; artificial intelligence; immunology
Special Issue Information
Dear Colleagues,
The advanced form of prostate cancer is designated metastatic castration-resistant prostate cancer (mCRPC), which spreads beyond the prostate gland and for which hormone therapy is no longer effective in slowing down disease progression. mCRPC occurs when prostate cancer evolves to resist standard treatment with androgen deprivation therapy (ADT), which blocks the production and signaling activity of hormones called androgens (such as testosterone) that ensure the cancer’s growth. An estimated 50% of diagnosed cases progress to mCRPC within 3 years of diagnosis and this aggressive form of the disease remains lethal despite therapeutic advances. Patients diagnosed with mCRPC have survival ranges from 3 to 78 months. mCRPC remains a clinically challenging late-stage cancer with no curative treatment options. The current treatment options available for mCRPC are the hormonal drugs enzalutamide (brand name XTANDI) and abiraterone (ZYTIGA, which is given with prednisone), which are often used as the first line of therapy for CRPC/mCRPC patients. Moreover, Docetaxel (chemotherapy) is used in patients who are non-responsive to enzalutamide or abiraterone. Recently, the clinical guidelines made some changes in the treatment of CRPC patients; now, mutational testing and the analysis of marker genes such as BRCA2, BRCA1, CHECK2, ATM, and a few others are clinically adaptive to predict the effectiveness of new treatments, including the immune system, In recent years, what has changed in the treatment of mCRPC is that clinical guidelines now include mutational testing and analysis of markers to predict the potential effectiveness of newer treatments that involve immunotherapy.
Dr. Shiv Verma
Dr. Vaibhav Singh
Dr. Man Mohan
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- castrate-resistant prostate cancer (CRPC)
- prostate cancer
- treatment
- a new therapy
- drug-resistant
- marker genes
- bone metastasis
- androgen receptor (AR)
- enzalutamid
- e abiraterone acetate
- Docetaxel
